Quantum BioPharma achieve 91% increase in Shareholder Equity and Liquidity in Q3 2026 as Lucid-MS Phase 2 Trial Advances into Study Start-Up
Key Highlights
- ➤Lucid-MS Phase 2 trial enters study start-up after FDA IND clearance and Thermo Fisher agreement
- ➤Shareholders’ equity rose 91% to US$9.77 million by September 30, 2026
- ➤Cash and digital assets totaled US$12.22 million, up from US$4.12 million at year-end
- ➤Nine-month operating expenses fell 32% to US$8.81 million
- ➤Quantum acquired 1,500,000 Unbuzzd shares, reaching a 19.87% ownership interest
Expert Statements
Zeeshan Saeed, Chief Executive Officer of Quantum BioPharma
“With FDA clearance in hand and our Study Start-Up Agreement signed with the clinical research business of Thermo Fisher Scientific, Lucid-MS has moved from planning into the implementation of its Phase 2 trial in progressive multiple sclerosis,”
Donal Carroll, Chief Financial Officer of Quantum BioPharma
“Shareholders’ equity has grown 91% since the start of the year to US$9.77 million, and working capital now stands at US$5.47 million, while we reduced total operating expenses by 32% over the first nine months of 2026 compared with the same period last year,”
TORONTO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) ("Quantum" or the "Company") reports its unaudited financial and operational results for the third quarter ended September 30, 2026.
As of September 30, 2026, cash and cash equivalents totaled approximately US$3.56 million and digital assets totaled approximately US$8.66 million, representing combined holdings of approximately US$12.22 million, compared with US$4.12 million as of December 31, 2025 (excluding US$1.60 million of digital assets that were restricted at that date). Total shareholders’ equity increased approximately 91% to US$9.77 million, from US$5.10 million at December 31, 2025.
Get started
Create a free account to read the full story.